Article Summary
赵 华,钟丽珍,张 微,王剑锋,程政平.丁苯酞联合美金刚对阿尔茨海默病患者氧化应激、内皮功能及认知功能的影响[J].现代生物医学进展英文版,2019,19(20):3904-3907.
丁苯酞联合美金刚对阿尔茨海默病患者氧化应激、内皮功能及认知功能的影响
Effects of Butylphthalide Combined with Memantine on Oxidative Stress, Endothelial Function and Cognitive Function in Patients with Alzheimer's Disease
Received:February 26, 2019  Revised:March 22, 2019
DOI:10.13241/j.cnki.pmb.2019.20.023
中文关键词: 丁苯酞  美金刚  阿尔茨海默病  氧化应激  内皮功能  认知功能
英文关键词: Butylphthalide  Memantine  Alzheimer's disease  Oxidative stress  Endothelial function  Cognitive function
基金项目:辽宁省医药卫生计划基金资助项目(20160415)
Author NameAffiliationE-mail
ZHAO Hua Second Department of Neurology, Dalian Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, 116033, China Dr_zhao123@yeah.net 
ZHONG Li-zhen Second Department of Neurology, Dalian Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, 116033, China  
ZHANG Wei Department of Geriatric, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116033, China  
WANG Jian-feng Second Department of Neurology, Dalian Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, 116033, China  
CHENG Zheng-ping Second Department of Neurology, Dalian Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, 116033, China  
Hits: 877
Download times: 671
中文摘要:
      摘要 目的:探讨丁苯酞联合美金刚对阿尔茨海默病(AD)患者氧化应激、内皮功能及认知功能的影响。方法:根据随机数表法将80例AD患者分为对照组(n=40,采用美金刚治疗)和研究组(n=40,采用丁苯酞联合美金刚治疗),比较两组患者临床疗效,并比较分析治疗前后氧化应激、内皮功能以及认知功能相关指标变化,观察两组不良反应发生情况。结果:研究组总有效率为87.50%,显著高于对照组的67.50%(P<0.05)。治疗6个月后,两组患者丙二醛(MDA)、β淀粉样蛋白(Aβ)水平均降低,且研究组低于对照组(P<0.05),两组患者超氧化物歧化酶(SOD)水平升高,且研究组高于对照组(P<0.05)。治疗6个月后,两组患者一氧化氮(NO)、血管内皮生长因子(VEGF)水平均升高,且研究组高于对照组(P<0.05)。治疗后第3个月、治疗后第6个月、治疗后第12个月,两组患者MMSE评分逐渐升高,且各时间点研究组MMSE评分均高于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:丁苯酞联合美金刚治疗AD患者疗效确切,可有效减轻患者氧化应激反应,提高患者内皮功能和认知功能,安全可靠。
英文摘要:
      ABSTRACT Objective: To investigate the effects of butylphthalide combined with memantine on oxidative stress, endothelial function and cognitive function in patients with Alzheimer's disease (AD). Methods: 80 patients with AD were randomly divided into control group (n=40, memantine therapy) and study group (n=40, butylphthalide combined with memantine therapy). The clinical effects of the two groups were compared. The changes of oxidative stress, endothelial function and cognitive function before and after treatment were compared and analyzed. The adverse reactions of the two groups were observed. Results: The total effective rate of the study group was 87.50%, which was significantly higher than that of the control group 67.50% (P<0.05). At 6 months after treatment, the levels of malondialdehyde (MDA) and β-amyloid protein (Aβ) decreased in the two groups, and those in the study group were lower than those in the control group (P<0.05). The levels of superoxide dismutase (SOD) increased in the two groups, and that in the study group was higher than that in the control group (P<0.05). At 6 months after treatment, the levels of nitric oxide (NO) and vascular endothelial growth factor (VEGF) in the two groups increased, and those in the study group were higher than those in the control group (P<0.05). At 3 months after treatment, 6 months after treatment and 12 months after treatment, the MMSE scores of the two groups increased gradually, and the MMSE scores of the study group were higher than those of the control group at each time point (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Butylphthalide combined with Memantine is effective in treating AD patients. It can effectively alleviate oxidative stress, improve endothelial function and cognitive function, and it is safe and reliable.
View Full Text   View/Add Comment  Download reader
Close